Richard A. Miller, M.D.
Co-Founder, President and CEO
Dr. Miller was co-founder and CEO of Pharmacyclics, where he led the initial discovery and development efforts for ibrutinib. Prior to that, he was a co-founder, Vice President and Director of IDEC (which merged to form Biogen IDEC, now Biogen), where he led research efforts on lymphoma culminating in the development of rituximab. He has also founded other private and public biotech companies. Dr. Miller received an M.D. from the State University of New York Medical School, summa cum laude. He is a board-certified oncologist and is currently Adjunct Clinical Professor of Medicine (oncology) at Stanford University Medical Center.
CHIEF FINANCIAL OFFICER
Mr. Lea served as the Chief Financial Officer of Pharmacyclics from 1998 to 2008. He received a B.S. in agricultural economics from the University of California, Davis, and an M.B.A. from the Anderson School at the University of California, Los Angeles.
Debra Horen, SPHR
Vice President Human Resources
Before joining Corvus Pharmaceuticals in 2018, Debra Horen, was the Managing Partner of Next Path Consulting, where she led HR departments and Talent Management initiatives at Genoptix, Cleave Biosciences, Stanford University, Genentech, and others. Prior to her time at Next Path, Ms. Horen served in leadership roles at several companies, including Amylin Pharmaceuticals, a Bristol-Myers Squibb Company, and Biogen. Ms. Horen completed the Executive Program at the Stanford University School of Business and received an M.A. in Educational Technology from San Francisco State University.
Daniel W. Hunt, J.D.
SENIOR VICE PRESIDENT AND CHIEF BUSINESS OFFICER
Mr. Hunt served as General Counsel and Vice President of Corporate Development at CoMentis, a biotech company, from 2009 to 2016. Mr. Hunt also served as CEO of TelomeHealth and Vice President of Business Development at Zosanopharma. Mr. Hunt was an Associate General Counsel at Genentech. Prior to that, he held senior legal and transactional positions at Abgenix, Roche and Chiron. Mr. Hunt received a B.S in biology from the University of Colorado at Boulder and a J.D. from the Boalt Hall School of Law at the University of California, Berkeley.
James W. Janc, Ph.D.
VICE PRESIDENT, PHARMACOLOGY
Dr. Janc was with Theravance from 2006 to 2015, most recently as Senior Director of Research Technology. From 2000 to 2006, he was with Celera Genomics, most recently as Senior Director of Enzymology. Dr. Janc earned a B.A. in biochemistry from the University of Maryland and a Ph.D. in biochemistry from the University of Wisconsin-Madison. He was a National Institutes of Health (NIH) Postdoctoral Fellow in the Department of Chemistry at Johns Hopkins University.
William Ben Jones, Ph.D.
SENIOR VICE PRESIDENT, PHARMACEUTICAL DEVELOPMENT
Dr. Jones was Director of Global Regulatory Affairs in Sanofi U.S.’s oncology business unit from December 2012 to December 2014. From 2008 to March 2012, he was Director of Project Management & Regulatory at Pharmacyclics, where he played a principal role in the development of ibrutinib. Prior to Pharmacyclics, he was Associate Director of Development at Plexxikon and Senior Project Manager at Vertex Pharmaceuticals. Dr. Jones earned a B.S. and a Ph.D. in chemistry from the University of Cincinnati and completed a post-doctoral fellowship at the University of Oxford.
Long Kwei, Ph.D.
VICE PRESIDENT, BIOMETRICS & CLINICAL OPERATIONS
Dr. Kwei was Executive Director of Biostatistics at Pharmacyclics from November 2013 to July 2017. Prior to that, he served as the Site Head of Biometrics at AbbVie, Abbott Labs and PDL Biopharma before Abbott acquired the company. Prior to PDL Biopharma, he was the Executive Director of Biometrics at Tularik, then Amgen after Amgen’s acquisition of the company. From 1996 to 2001, he was with Roche, where he was the Site Head of Biometrics. Dr. Kwei earned a Ph.D. in biostatistics from the University of California, Berkeley.
Mehrdad Mobasher, M.D., MPH
VICE PRESIDENT AND CHIEF MEDICAL OFFICER
Dr. Mobasher joined Corvus in January 2019 from Genentech/ Roche where he worked from 2010 to 2018, most recently as a Group Medical Director and Development Lead for venetoclax. Dr. Mobasher steered the clinical development efforts for venetoclax through four successful Breakthrough Therapy designations from the FDA and three approvals granted under FDA’s priority review, two of which were under accelerated approval. He also was an adjunct clinical faculty member in the Division of Medical Oncology at Stanford University. Dr. Mobasher is the author of numerous papers published in peer-reviewed medical journals and multiple abstracts presented at medical conferences. Dr. Mobasher received an M.D. from Tehran University of Medical Sciences, and an M.P.H. in general epidemiology from the School of Public Health at the University of Michigan. He completed an internship and residency in internal medicine at the University of California, Irvine, and post-doctoral fellowships in hematology and medical oncology at Stanford University.
Erik Verner, Ph.D.
VICE PRESIDENT OF CHEMISTRY RESEARCH
Dr. Verner served as Director of Chemistry at Principia Biopharma from March 2011 to December 2014. Prior to that, he was with Pharmacyclics, where he served as Director of Chemistry from 2008 to February 2011 and principal scientist from 2006 to 2008. At Pharmacyclics, Dr. Verner was a co-inventor of ibrutinib and served as the lead chemist on the program. From 1996 to 2006, he served as a principal scientist at Axys Pharmaceuticals (formerly Arris Pharmaceuticals) and Celera Corporation, a subsidiary of Axys Pharmaceuticals. Dr. Verner earned a B.S. in chemistry from the University of Idaho and a Ph.D. in organic chemistry from the University of Pittsburgh.
Joseph J. Buggy, Ph.D.
CO-FOUNDER AND CONSULTANT
Dr. Buggy was with Pharmacyclics from 2006 to August 2013, where he was Vice President, Research from 2007 to August 2013, and served as project leader of the BTK inhibitor ibrutinib program. From 2001 to 2006, he was with Celera Genomics, where he served as Director in the Department of Biology, and, prior to that, Principal Scientist. Dr. Buggy earned a B.S. in microbiology from the University of Pittsburgh and a Ph.D. in molecular, cellular and development biology from Indiana University.
Board of Directors
Ian T. Clark
Mr. Clark has more than 34 years of experience in the biotechnology and pharmaceutical industry, most recently serving as CEO and member of the board of directors for Genentech, until his retirement in 2016.
During his seven-year tenure as CEO, Ian and his team brought eleven new medicines to market for patients fighting rheumatoid arthritis, idiopathic pulmonary fibrosis and various types of cancer. Ian was among the highest rated CEOs by Glassdoor, recognized as the Bay Area’s most admired CEO by the San Francisco Business Times and awarded the Honorable Mentor of the Year by the Heath Business Woman's Association.
Prior to joining Genentech, Ian held various positions of increasing responsibility at Novartis, Sanofi, Ivax and Searle, working in the USA, UK, Canada, Eastern Europe and France.
Currently, Ian is on the board of directors for Takeda, Agios Pharmaceuticals, Guardant Health, Forty Seven, Avrobio. He is an Operating Partner of Blackstone Life Sciences. He is also on the BioFulcrum Board of the Gladsone Institute.
Ian previously served on the Boards of Shire, Kite Pharma, Dendreon, Solazyme and Vernalis. He was also on the Board of Biotechnology Industry Association and on the Economic Advisory Council of the 12th District of the Federal Reserve.
Ian received his bachelor of science in Biological Sciences and an Honorary Doctorate of Science from Southampton University in the United Kingdom.
Elisha P. (Terry) Gould
Mr. Gould is a Partner and Head of Venture/Growth Equity Investments with Adam Street Partners. He invests in venture and growth-oriented companies with a focus on the healthcare space. Mr. Gould also sits on the board of directors of OncoMed Pharmaceuticals, Inc., LifeBond, Ltd. and Orbus Therapeutics, Inc. He is a former board member at Naurex, Inc. (acquired by Allergan plc), INC Research, Inc., Incline Therapeutics, Inc. (acquired by the Medicines Company) and Proteus Biomedical, Inc. Mr. Gould is also a member of the Adams Street Executive and Direct Investment Committees.
Linda S. Grais, M.D., J.D.
Dr. Grais was president and chief executive officer of Ocera Therapeutics, Inc., a biopharma company developing new treatments for serious liver disease, until its acquisition by Mallinckrodt. Prior to that, she was a partner at InterWest Partners, a venture capital firm focused on biotechnology and medical device companies. Previously, Dr. Grais was a founder and executive vice president of Structural GenomiX, Inc., a drug discovery company focusing on new treatments for cancer that was acquired by Eli Lilly & Co. Earlier in her career, she was a corporate attorney at Wilson Sonsini Goodrich & Rosati, where she represented life science companies in venture financings, public offerings and strategic partnerships. Before practicing law, Dr. Grais worked as an assistant professor in the Department of Internal Medicine at the University of California, San Francisco. Dr. Grais currently serves on the board of directors of PRA Health Sciences, a large contract research organization, and serves on its Audit Committee. She also is on the board of directors of ARCA biopharma and Zosano Pharma. Dr. Grais received a B.A. in philosophy from Yale University, an M.D. from Yale Medical School, and a J.D. from Stanford Law School.
Steve E. Krognes
Mr. Krognes is Chief Financial Officer of Denali Therapeutics Inc., a biotechnology company. He served as Senior Vice President and Chief Financial Officer at Genentech, Inc., and Head of Mergers & Acquisitions at Roche Holding AG. Mr. Krognes is also a member of the board of directors of Gritstone Oncology, a public biotechnology company, the California Academy of Sciences, a scientific and educational institution, and was previously a member of the board of directors and board executive committee of the California Life Sciences Association, an industry organization. Mr. Krognes received a B.S. in economics from the Wharton School of the University of Pennsylvania and an M.B.A. from Harvard Business School.
Richard A Miller, M.D.
Dr. Miller was co-founder and CEO of Pharmacyclics, where he led the initial discovery and development efforts for ibrutinib. Prior to that, he was a co-founder, Vice President and Director of IDEC (which merged to form Biogen IDEC, now Biogen), where he led research efforts on lymphoma culminating in the development of rituximab. He has also founded other private and public biotech companies. Dr. Miller received an M.D. from the State University of New York Medical School. He is a board-certified oncologist and is currently Adjunct Clinical Professor of Medicine (oncology) at Stanford University Medical Center.
Edith P. Mitchell, M.D.
Edith P. Mitchell, M.D., has more than 45 years of experience treating and researching cancer, including prominent roles with medical societies and cancer organizations, and is a retired United States Air Force Brigadier General. Dr. Mitchell has authored and co-authored more than 150 articles and book chapters as well as many abstracts on cancer treatment, prevention, and cancer control.
Dr. Mitchell currently serves as clinical professor, Department of Medicine and Medical Oncology at Sidney Kimmel Medical College at Thomas Jefferson University, and associate director for Diversity Programs and director of the Center to Eliminate Cancer Disparities for the Sidney Kimmel Cancer Center at Thomas Jefferson University. In addition, she serves on the National Cancer Institute (NCI) Review Panel and the Cancer Investigations Review Committee, the Clinical Trials and Translational Research Advisory Committee, serves as co-chair of the NCI Disparities Committee, and is a member of the NIH Council of Councils. Because of her experience in the cancer research community, Dr. Mitchell was selected to serve as a member of the NCI’s Blue Ribbon Panel convened to advise the National Cancer Advisory Board on Vice President Biden’s National Cancer Moonshot Initiative.
In addition to her medical achievements, Dr. Mitchell is a retired United States Air Force Brigadier General, having served as the Air National Guard Assistant to the Command Surgeon for U.S. Transportation command and headquarters Air Mobility Command (AMC) based at the Scott Air Force Base in Illinois. General Mitchell has been awarded over 15 military service medals and ribbons including the Legion of Merit, Meritorious Service Medal, Air Force Achievement and Commendation Medals, National Defense Service Medal, and Humanitarian Service Medal. Dr. Mitchell holds a B.S. in biochemistry from Tennessee State University and an M.D. from Medical College of Virginia. She completed a residency at Meharry Medical College and a fellowship at Georgetown University Hospital. She is board-certified in internal medicine and medical oncology.
Scott W. Morrison
Mr. Morrison was a Partner with Ernst & Young LLP from 1996 to December 2015, where he also served as U.S. Life Sciences Leader from 2002 through December 2015. Mr. Morrison has held roles on the boards of directors of numerous life sciences industry organizations. Since January 2016, Mr. Morrison has served on the board and chairs the audit committees of Global Blood Therapeutics (GBT) and Audentes Therapeutics. Since 1999, he has served on the board of directors of the Biotechnology Institute, a nonprofit organization, where he has served on the audit committee since 2002. Mr. Morrison also serves on the board of directors of Symic Bio, Inc., and Ideaya Biosciences Inc., privately held biotechnology companies. Mr. Morrison previously served on the boards of directors of the Life Sciences Foundation, a biotechnology nonprofit organization, the Bay Area Biosciences Association, a 501(c)(3) organization, and the Emerging Companies Section of the Biotechnology Industry Organization (BIO), a trade organization.
Peter Thompson, M.D.
Dr. Thompson is currently a Private Equity Partner with OrbiMed Advisors and has over 20 years of industry experience. He co-founded and was CEO of Trubion Pharmaceuticals, co-founded Cleave BioSciences, and serves as a director on the boards of several public and private companies. He previously held executive positions at Chiron Corporation and Becton Dickinson. Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an Affiliate Professor of Neurosurgery at the University of Washington, an inventor on numerous patents, and a board-certified internist and oncologist.